Gingko biloba
Phase 3Small molecule
Boehringer IngelheimGingko biloba is one of 61 small molecule programs targeting Glaucoma. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Gingko biloba
Boehringer IngelheimPhase 3
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Glaucoma1 trial
Impact of Oral Versatile Antioxidants on Glaucoma Progression
Completed·—·Phase 3·NCT01544192·60 enrolled
Drug Interactions1 trial
Vascular Function1 trial
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00029991·100 enrolled
Asthma1 trial
Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00029679·280 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gingko biloba. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company